ポスター発表資料
Long-term treatment with imeglimin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes (TIMES 2) (Phase 3)
J. Dubourg et al. — September 2020, Virtual Conference
Efficacy And Safety Of Imeglimin In Combination With Insulin In Japanese Patients With Type 2 Diabetes: Results of TIMES 3 Trial (Phase 3)
J. Dubourg et al. — September 2020, Virtual Conference
Chronic Treatment With The Direct AMP Kinase Activator PXL770 Improves Cardiac And Renal Function In Diabetes Related Cardiorenal Syndrome
Y. Stephan et al. — September 2020, Virtual Conference
Phase 1 Study of PXL065 Confirms Dose-Proportionality & Stabilization of the Preferred Stereoisomer (R-Pioglitazone) for the Treatment of NASH
Bolze et al. — November 2019, Boston, MA, USA
Safety, Tolerability & PK of PXL065*, the Stabilized R-Stereoisomer of Pioglitazone: A Mitochondrial Function Modulator for NASH without PPARγ Agonism & Related Side Effects
Vincent Jacques et al. — November 2018, San Francisco, USA
PXL770, a New Direct AMP Kinase Activator, Acting on the Adipose Tissue and the Liver, Demonstrates Promising Effects for Treatment of Non-Alcoholic Steatohepatitis
Pascale Gluais-Dagorn et al. — November 2018, San Francisco, USA
PXL770, a direct AMPK activator, shows favorable cardiac safety profile
Sophie Hallakou-Bozec et al. — October 2018, Toronto, Canada
PXL770, a direct AMPK activator for the treatment of NASH, shows a favorable PK, tolerability and safety profile in humans
Sandrine Perrimond-Dauchy et al. — October 2018, Toronto, Canada
Imeglimin Protects Ins-1 Cells And Human Islets Against High Glucose- And High Fructose-induced Cell Death By Inhibiting The Mitochondrial PTP Opening
Sandrine Lablanche et al. — June 2018, Orlando, USA
PXL770, a new direct AMP Kinase activator, demonstrates promising effects for treatment of non-alcoholic steatohepatitis
Pascale Gluais-Dagorn et al. — February 2018, London, UK
Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial
J. Dubourg — September 2017, Lisbon, Portugal
Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Marianne Lachaux et al. — August 2017, Barcelona, Spain
Imeglimin Opposes Development of Metabolic Syndrome Related Diabetic Cardiomyopathy
Marianne Lachaux et al. — June 2017, San Diego, USA
Imeglimin Preserves β-cell Function and Mass in Male Zucker Diabetic Fatty Rats World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
Sophie Hallakou-Bozec et al. — December 2016, Los Angeles, California, USA
Efficacy of DRX-065, the stabilized R-enantiomer of pioglitazone (pio), in choline-deficient (CD) and methionine/choline-deficient (MCD) diet mouse models of nonalcoholic steatohepatitis (NASH)
Sharon C. Cheetham et al. — November 2016, Nottingham, UK
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mouse model of obesity and diabetes EASD,
Sébastian Bolze et al. — September 2016, Munich, Germany
PXL770, a Novel Direct AMPK Activator, Inhibits Hepatic de novo Lipogenesis for the Treatment of Metabolic Disorders EASD
Sophie Hallakou-Bozec et al. — September 2016, Munich, Germany
Imeglimin Improves Vascular Dysfunction in Type 2 Diabetes Animal Models EASD
Fouqueray P et al. — September 2016, Munich, Germany
Imeglimin Improves Insulin Sensitivity in an Adult STZ Rat Model ADA
Sophie Hallakou-Bozec et al. — June 2016, New Orleans, USA
Imeglimin Increases Insulin Secretion in Response to Glucose as a Unique Mechanism of Action Depending on NAD Synthesis ADA
Sophie Hallakou-Bozec et al. — June 2016, New Orleans, USA
PXL770 Demonstrates Therapeutic Potential as a New Direct AMP Kinase Activator WCIRDC
Sophie Hallakou-Bozec et al. — November 2015, Los Angeles, USA
Imeglimin, a New Oral Anti-Hyperglycemic Agent Controls Fasting and Post-Prandial Glucose through an Improvement in both Insulin Secretion and Insulin Sensitivity WCIRDC
Fouqueray P et al. — November 2015, Los Angeles, USA
Dose Ranging-Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes.
Fouqueray P et al. — June 2015, Boston, USA
Imeglimin decreases hepatic glucose production through a unique mitochondrial mechanism of action.
Vial G et al. — June 2014, San Francisco, USA
Imeglimin: A new antidiabetic agent that provides added benefit to DPP-4 inhibitor therapy.
Fouqueray P et al. — June 2013, Chicago, USA
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy
Fouqueray P et al. — June 2012, Philadelphia, USA
The effects of the antidiabetic Imeglimin in hyperglycemic mice with septic shock.
Wagner F et al. — March 2012, Brussels, Belgium
Imeglimin, a novel glimin oral anti-diabetic, exhibits good glycemic control in type 2 diabetic patients.
Pirags V et al. — September 2010, Stockholm, Sweden